Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.

Cambridge UK, January 2013 – Antitope Ltd., UK (“Antitope”) today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA (“NeuroPhage”) for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it’s Composite ProteinTM deimmunisation technology to a next generation treatment for neurodegenerative diseases.

“We are delighted to be working with such an innovative company as NeuroPhage,” said Dr Matthew Baker, Chief Executive Officer and co-founder of Antitope, adding “This partnership utilises Antitope’s expertise in engineering non-immunogenic proteins to complement NeuroPhage’s innovations in developing novel therapeutics based on clearance of pathological protein aggregates.”

About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope’s proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of proteins and humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

About NeuroPhage Pharmaceuticals, Inc.

NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA, USA, along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

Media Contact
Sarah Sutton
Ten Bridge Communications